Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18220717rdf:typepubmed:Citationlld:pubmed
pubmed-article:18220717lifeskim:mentionsumls-concept:C0013227lld:lifeskim
pubmed-article:18220717lifeskim:mentionsumls-concept:C0003402lld:lifeskim
pubmed-article:18220717lifeskim:mentionsumls-concept:C0011882lld:lifeskim
pubmed-article:18220717lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:18220717lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:18220717lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:18220717lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:18220717lifeskim:mentionsumls-concept:C1521840lld:lifeskim
pubmed-article:18220717pubmed:issue1lld:pubmed
pubmed-article:18220717pubmed:dateCreated2008-1-28lld:pubmed
pubmed-article:18220717pubmed:abstractTextWhile increasing antioxidant potential is an attractive treatment strategy for diabetic neuropathy, many years of trials using high-dose oral antioxidants have not produced therapeutic results. An increasing understanding of the innate antioxidant response and the pharmacological agents that can regulate this mechanism may open new avenue for drug development. This review describes the current state of antioxidant trials and the potential for targeting the antioxidant response. In combination with antihyperglycemic agents, agents that regulate the antioxidant response may afford superior protection against cellular oxidative injury in diabetes.lld:pubmed
pubmed-article:18220717pubmed:languageenglld:pubmed
pubmed-article:18220717pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18220717pubmed:citationSubsetIMlld:pubmed
pubmed-article:18220717pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18220717pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18220717pubmed:statusMEDLINElld:pubmed
pubmed-article:18220717pubmed:monthJanlld:pubmed
pubmed-article:18220717pubmed:issn1873-5592lld:pubmed
pubmed-article:18220717pubmed:authorpubmed-author:SadidiMahdieh...lld:pubmed
pubmed-article:18220717pubmed:authorpubmed-author:EdwardsJames...lld:pubmed
pubmed-article:18220717pubmed:authorpubmed-author:FeldmanEva...lld:pubmed
pubmed-article:18220717pubmed:authorpubmed-author:VincentAndrea...lld:pubmed
pubmed-article:18220717pubmed:issnTypeElectroniclld:pubmed
pubmed-article:18220717pubmed:volume9lld:pubmed
pubmed-article:18220717pubmed:ownerNLMlld:pubmed
pubmed-article:18220717pubmed:authorsCompleteYlld:pubmed
pubmed-article:18220717pubmed:pagination94-100lld:pubmed
pubmed-article:18220717pubmed:meshHeadingpubmed-meshheading:18220717...lld:pubmed
pubmed-article:18220717pubmed:meshHeadingpubmed-meshheading:18220717...lld:pubmed
pubmed-article:18220717pubmed:meshHeadingpubmed-meshheading:18220717...lld:pubmed
pubmed-article:18220717pubmed:meshHeadingpubmed-meshheading:18220717...lld:pubmed
pubmed-article:18220717pubmed:meshHeadingpubmed-meshheading:18220717...lld:pubmed
pubmed-article:18220717pubmed:meshHeadingpubmed-meshheading:18220717...lld:pubmed
pubmed-article:18220717pubmed:meshHeadingpubmed-meshheading:18220717...lld:pubmed
pubmed-article:18220717pubmed:meshHeadingpubmed-meshheading:18220717...lld:pubmed
pubmed-article:18220717pubmed:meshHeadingpubmed-meshheading:18220717...lld:pubmed
pubmed-article:18220717pubmed:meshHeadingpubmed-meshheading:18220717...lld:pubmed
pubmed-article:18220717pubmed:year2008lld:pubmed
pubmed-article:18220717pubmed:articleTitleThe antioxidant response as a drug target in diabetic neuropathy.lld:pubmed
pubmed-article:18220717pubmed:affiliationDepartment of Neurology, University of Michigan, Ann Arbor, MI 48109, USA. andreav@umich.edulld:pubmed
pubmed-article:18220717pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18220717pubmed:publicationTypeReviewlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18220717lld:pubmed